Strategic services and solutions to help organizations compete in an evolving health market and improve cost-efficiency and profitability
Pharmaceutical and Life Sciences companies are facing unprecedented challenges globally and must have the scientific, commercial, and operational capabilities necessary to thrive in an increasingly complex health care environment and emerge stronger. We work with organizations across the industry value chain - from Biotech to Big Pharma and from CRO to Medical Device - to innovate, thrive and grow, from strategy through execution.
PwC’s Health Research Institute examines the top health industry issues of 2021 including virtual health, clinical trial disruption, M&A, resilient supply chains and interoperability.
In the current environment of poor product pipelines and broader customer bases, the traditional sales and marketing model of driving revenue with ever larger sales forces is no longer sustainable. Pharmaceutical and med device companies need to achieve both commercial and operational efficiency to secure their success. Let us help you effectively manage the new obstacles you’re facing today to ensure your organization remains stable and profitable.
Companies are addressing important questions about existing and future revenue generation, and how to align operational and financial tactics to enable their chosen corporate strategy. We are working with our clients to explore strategic options and begin the process today of restructuring their business for tomorrow. We help to identify those areas with the most realistic potential and devise and review pragmatic business plans that maximise value. We know the difficult decisions and trade-offs that executives face when managing their businesses, allocating resources or contemplating deals. We know the traps of large and small company cultures. Mergers and acquisitions are vital to corporate strategy. Most companies will use some form of equity or debt finance to fund future plans, and Life Sciences companies often use private equity or an initial public offering (IPO). Whatever the new venture, buying at the price, integrating the different elements, and ensuring tax efficiencies throughout is key to ensuring maximum value.
Together with our clients, we use a combination of industry, data, analytical and technology expertise to develop process improvements that assist you in gaining value from technology investments. We bring knowledge in IT strategy, enterprise applications, and analytical technologies, as well as the experience of our advisors who have worked within R&D, Supply chain and manufacturing within the industry.
We work closely with our clients to drive innovation and advance the development of products to bring to patients. We work with Pharma leaders to help their organizations optimize performance while balancing quality and regulatory requirements. Our advisors have a wealth of industry based R&D functional expertise and strategic consulting experience with a deep understanding of finance, tax, risk management, compliance, operations and human resources. With this breadth of capabilities, we are able to help our clients effectively evaluate, plan and execute on their scientific, clinical, quality, and regulatory objectives.
The Pharmaceutical and life sciences industries are among the most heavily regulated in the world. The regulatory and tax environments are continuously changing in response to globalization, emerging markets, increasing complexity of disease targets, introduction of new technologies and the rising sophistication and demands of both patients and regulators.
Keeping pace with changing regulation requires good processes and procedures which ensure adherence and enable effective global, national and local management. We work with our clients to audit and develop management systems which enable greater transparency across the firm, inform the development of new approaches to a broad range of regulatory and tax compliance, and help improve performance.
Quality Management is rapidly transforming across the industry. The expectations of both Patients and Regulators are increasing at a rapid pace. Quality expectations are evolving from a compliance-centric mindset to a Product and Innovation-centric mindset (or Big “Q”). It is no longer sufficient to just meet the minimal regulatory requirements. In successful companies, the CxO suite is embracing this new mindset and driving Quality throughout the organization.
Executives are realizing that embracing Big “Q” can improve the brand image, accelerate new product introductions and reduce operating expenses. To help drive these benefits, executives are looking to “digitize” Quality so information can be used to help drive proactive decision making. This represents a cultural shift -- one that requires the Quality Unit to transform and become a trusted business partner with the rest of the organization. PwC is a leader in helping companies drive and achieve these Cultural and Digital Quality transformations.
In today’s uncertain environment, organizations are facing new and unique supply chain challenges. Having active visibility of critical supply chain components / materials, interdependencies, and data to properly assess potential operational and financial risk is more crucial than ever before. Companies need to plan and manage immediate contingencies, and create a more resilient supply chain in the longer-term.
At PwC, we are focused on tailoring our services to help you remain agile and resilient in response to your supply chain issues. We work with our clients to identify options from integrated planning through distribution, understand potential risks, and design / implement solutions to assure supply continuity, improve delivery performance, and reduce costs.
